Swiss National Bank Iveric Bio, Inc. Transaction History

Swiss National Bank

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$26.24 - $39.63 $209,920 - $317,040	8,000 Added 3.25%	254,000 $9.99 Million
Q1 2023 May 10, 2023	SELL	$18.67 - $24.56 $545,164 - $717,152	-29,200 Reduced 10.61%	246,000 $5.99 Million
Q4 2022 Feb 08, 2023	BUY	$17.24 - $23.95 $1.41 Million - $1.96 Million	82,000 Added 42.44%	275,200 $5.89 Million
Q3 2022 Nov 09, 2022	BUY	$9.4 - $18.59 $31,960 - $63,206	3,400 Added 1.79%	193,200 $3.47 Million
Q1 2022 May 09, 2022	BUY	$12.15 - $16.83 $360,855 - $499,850	29,700 Added 18.55%	189,800 $3.19 Million

Q4 2021 Feb 08, 2022	BUY	$13.83 - $18.78 $207,450 - $281,700	15,000 Added 10.34%	160,100 $2.68 Million
Q3 2021 Nov 08, 2021	BUY	$7.07 - $17.5 $188,062 - $465,500	26,600 Added 22.45%	145,100 $2.36 Million
Q2 2021 Aug 06, 2021	SELL	$5.69 - $7.17 $246,946 - $311,178	-43,400 Reduced 26.81%	118,500 $748,000
Q4 2020 Feb 05, 2021	BUY	$5.65 - $7.66 $914,735 - $1.24 Million	161,900 New	161,900 $1.12 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.